A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.
Compared with chemotherapy, neoadjuvant chemoimmunotherapy led to better event-free survival and complete responses but not overall survival in patients with resectable non–small cell lung cancer who had baseline tumor programmed death–ligand 1 below 1%, a recent meta-analysis found.
To clarify the efficacy of neoadjuvant chemoimmunotherapy across patient subgroups, researchers conducted a meta-analysis of 43 studies, including eight randomized controlled trials, with a total of 5431 patients. Neoadjuvant chemoimmunotherapy was also associated significantly higher odds for major pathologic responses and complete response .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
No Benefit to Adding Chemo to Immunotherapy in Older Adults With NSCLCAdding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.
Read more »
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesGastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy responses for these tumors.
Read more »
AI predicted brain metastasis in lung cancer patients more accurately.Artificial intelligence deep learning predicts if a patient’s non-small cell lung cancer (NSCLC) will spread to the brain better than expert pathologists.
Read more »
– Thoracic and Head & Neck Medical Oncology - Houston, Texas (US) job with The University of Texas MD Anderson Cancer CenterPostdoctoral Fellow – Thoracic and Head &Neck Medical Oncology – KRAS-mutant non-small cell lung cancer (NSCLC) Postdoctoral positions are available to study molecular mechanisms associated with therapeutic response and resistance to RAS inhibition in non-small cell lung cancer (NSCLC) in the laboratory of Ferdinandos Skoulidis, MD, PhD at...
Read more »
Balancing Act: San Antonio creative Analy Diego multitasks in styleBorn in Laredo and raised across the U.S.-Mexico border in Nuevo Laredo, Analy Diego felt the pull of art from an early age — thanks largely to the influence of her grandfather Miguel Angel Patino, who once worked as a movie poster artist.
Read more »
No Benefit to Adding Chemo to Immunotherapy in Older Adults With NSCLCAdding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.
Read more »